BEAM: Beam Therapeutics Inc

BEAM Notícias

• 14:22 Can CRSP's In Vivo Pipeline Aid Long-Term Growth Beyond Casgevy?
• 12:48 CRSP vs. BEAM: Which Gene Editing Stock Holds More Potential Right Now?
• 15:15 CRISPR Therapeutics Gains 41.4% in 3 Months: How to Play the Stock
• 00:03 Cathie Wood’s ARK buys Robinhood, CRISPR, sells Genius Sports stock
• 11:47 Cantor Fitzgerald reiterates Overweight rating on Beam Therapeutics stock
• 00:05 Cathie Wood’s ARK ETF bolsters biotech, trims defense stock
• 14:50 Beam Therapeutics: A Slow-Developing Story (NASDAQ:BEAM)
• 19:35 Pfizer's Investigational Drug Flunks Late-Stage For Sickle Cell Disease - Pfizer (NYSE:PFE)
• 12:40 Beam Therapeutics stock surges after FDA grants RMAT designation
• 11:05 FDA grants RMAT designation to Beam Therapeutics’ sickle cell therapy
• 15:40 Can Rising Casgevy Sales Aid CRISPR Therapeutics Post Q2 Earnings?
• 01:09 Tracking Cathie Wood’s ARK Invest 13F Portfolio – Q2 2025 Update (BATS:ARKK)
• 15:51 BEAM's Q2 Loss Narrower Than Expected, Revenues Miss Mark
• 17:39 Clear Street reiterates Buy rating on Beam Therapeutics stock at $34
• 14:19 Beam earnings beat by $0.11, revenue fell short of estimates
• 12:15 Beam Therapeutics Inc. (BEAM) Reports Q2 Loss, Misses Revenue Estimates
• 14:00 Vir Biotechnology, Inc. (VIR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
• 13:44 3 Genomics Stocks Worth Adding to Your Portfolio in 2025
• 14:00 Will Beam Therapeutics Inc. (BEAM) Report Negative Q2 Earnings? What You Should Know
• 00:06 Cathie Wood’s ARK buys Tempus AI stock, sells Block and Roku
• 00:08 Cathie Wood’s ARK buys CRSP stock, sells ROKU and MASS
• 15:17 Cathie Wood shells out $13.9 million for one high-stakes biotech stock
• 00:09 Cathie Wood’s ARK ETF bolsters Beam stock, sheds Roblox
• 00:07 Cathie Wood’s ARK adjusts with Beam, Compass, and Komatsu trades